Blood glucose level control

Abstract

A method of glucose level control comprising, providing at least one electrode adapted to apply an electric field to a pancreas; and applying an electric field to the pancreas using said at least one electrode such that blood glucose levels are significantly reduced and blood insulin levels are not significantly increased compared to a regular insulin response in a same person.

Description

RELATED APPLICATIONS [0001] This application is a continuation in part of U.S. application Ser. No. 10 / 804,560 filed on Mar. 18, 2004 and PCT Application No. PCT / IL03 / 00736, filed on Sep. 4, 2003, which is a continuation-in-part of U.S. application Ser. No. 10 / 237,263, filed on Sep. 5, 2002, which is a continuation-in-part of PCT Application No. PCT / IL00 / 00566, filed on Sep. 13, 2000, now published as WO 01 / 66183, which designates the US. This application is also a continuation-in-part of PCT Application No. PCT / IL00 / 00132, filed on Mar. 5, 2000, which designates the US, now U.S. application Ser. No. 09 / 914,889, filed on Jan. 24, 2002. This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60 / 123,532, filed on Mar. 5, 1999. This application also claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 60 / 488,964, filed on Jul. 21, 2003. This application is also related to PCT publication WO 99 / 03533. The disclosures of a...

AI Technical Summary

Benefits of technology

[0012] An aspect of some embodiments of the invention relates to reducing glucose levels while not appreciably increasing insulin levels, at least not for more than small amounts and / or short periods of time and / or compared to a regular response in a same person. In an exemplary embodiment of the invention, an electric field is applied to a pancreas in a manner which reduces blood glucose levels and does not significantly raise insulin levels or even reduces such insulin levels. In an exemplary embodiment of the invention, reducing glucose levels prevents insulin levels from rising. This may have a beneficial effect on the pancreas by preventing exhaustion. In an exemplary embodiment of the invention, insulin is not raised by more than 20%, 15%, 10%, 5% or less, or even reduced, by 5%, 10% or more. A duration of insulin raise may be, for example, limited to less than 10 minutes, less than 5 minutes or less than 1 minute.

Problems solved by technology

In others, the required insulin is generated, but only at an unacceptable delay after the increase in blood glucose levels.

Although continuous control (e.g., avoiding dangerous spikes and dips) of blood glucose level is desirable, it cannot currently be achieved in some patients.

However, one limitation of the methods described in the Medtronic PCT publication is that increasing the burst rate may increase the level of intra-cellular calcium in the beta cells over a long period of time, without the level being allowed to go down, during intra-burst intervals.

This increase may cause various cell death mechanisms to be activated and / or otherwise upset the normal balance of the beta cell, eventually killing the cell.

In addition, such high calcium levels may cause hyper-polarization of beta cells, thereby reducing insulin secretion and preventing propagation of action potentials.

To date, no working electrical pancreatic control device is known.

Images